Valuation: AbbVie Inc.

Capitalization 372B 315B 290B 274B 512B 34,622B 521B 3,414B 1,336B 16,633B 1,396B 1,366B 59,062B P/E ratio 2026 *
23.7x
P/E ratio 2027 * 18.7x
Enterprise value 424B 359B 331B 312B 583B 39,448B 594B 3,890B 1,522B 18,951B 1,590B 1,556B 67,295B EV / Sales 2026 *
6.32x
EV / Sales 2027 * 5.69x
Free-Float
96.39%
Yield 2026 *
3.29%
Yield 2027 * 3.43%
1 day-0.08%
1 week+1.88%
Current month-3.32%
1 month-4.29%
3 months-5.24%
6 months-8.24%
Current year-7.98%
1 week 203.01
Extreme 203.01
214.1
1 month 201.66
Extreme 201.6634
224.37
Current year 201.66
Extreme 201.6634
237.11
1 year 168.54
Extreme 168.54
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
+1.84%+1.88%+17.40%+30.12% 372B
-0.76%-0.92%+22.29%+146.18% 825B
+0.90%+0.71%+55.55%+44.78% 578B
+1.73%+1.38%+25.39%+13.94% 326B
+0.97%-1.17%+46.28%+27.18% 314B
-0.16%+0.57%+51.52%+4.03% 296B
+0.25%-0.48%+33.70%+36.89% 294B
+0.32%+3.22%+19.40%+40.38% 189B
+1.02%+1.19%+31.88%+69.22% 174B
+3.66%+5.85%-40.29%-56.31% 172B
Average +0.82%+1.00%+26.31%+35.64% 354.17B
Weighted average by Cap. +0.52%+0.50%+30.28%+54.46%

Financials

2026 *2027 *
Net sales 67.06B 56.83B 52.35B 49.42B 92.28B 6,243B 93.95B 616B 241B 2,999B 252B 246B 10,650B 72.49B 61.44B 56.59B 53.42B 99.75B 6,749B 102B 665B 260B 3,242B 272B 266B 11,513B
Net income 16.23B 13.76B 12.67B 11.96B 22.34B 1,511B 22.74B 149B 58.32B 726B 60.91B 59.63B 2,578B 19.78B 16.77B 15.44B 14.58B 27.22B 1,842B 27.72B 182B 71.08B 885B 74.24B 72.67B 3,142B
Net Debt 51.84B 43.94B 40.47B 38.21B 71.34B 4,826B 72.63B 476B 186B 2,319B 195B 190B 8,233B 40.26B 34.12B 31.43B 29.67B 55.4B 3,748B 56.4B 370B 145B 1,800B 151B 148B 6,393B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
14/04/26 210.26 $ +1.84% 6,199,445
13/04/26 206.47 $ -0.71% 7,532,517
10/04/26 207.94 $ -2.10% 4,633,169
09/04/26 212.40 $ +0.38% 4,478,093
08/04/26 211.59 $ +2.53% 5,477,736
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
210.26USD
Average target price
249.00USD
Spread / Average Target
+18.42%

Quarterly revenue - Rate of surprise